After first collaborating on an AI software licensing agreement three years ago, Eli Lilly and Insilico Medicine are expanding their partnership through a new drug discovery and development deal that could be worth up to $2.75 billion.
The agreement builds on a separate $100 million collaboration signed in November 2025 and is designed to further extend Lilly’s access to Insilico’s AI-driven platform for identifying and developing new therapies. The companies initially partnered in 2023 through a licensing arrangement focused on AI tools.
Under the latest deal, Insilico Medicine will receive $115 million upfront, along with the potential for additional payments tied to meeting development, regulatory and marketing objectives. The agreement also includes tiered royalties on any resulting product sales, according to a March 29 announcement.
As part of the collaboration, Insilico will grant Eli Lilly exclusive global rights to develop, manufacture and commercialize certain preclinical oral drug candidates for indications not yet disclosed. The two companies will also work together on research and development for programs selected by Lilly.
Founder and CEO Alex Zhavoronkov said the Massachusetts-based company is focused on addressing diseases with significant unmet medical need, highlighting the capability of its AI platform to identify biological targets that may play roles across multiple conditions simultaneously.
Founded in 2014 by Zhavoronkov, Insilico Medicine began as an effort to reduce reliance on animal testing by using AI to model how compounds affect cellular systems. The company has since become a prominent partner for AI-driven drug design while also advancing its own internal pipeline focused on areas such as fibrosis and longevity.
Following a $293 million IPO in Hong Kong late last year, Insilico Medicine has continued to strike new partnerships. These include a potential $888 million discovery and development deal with Servier, a $120 million agreement with Qilu Pharmaceutical focused on cardiometabolic diseases, and a collaboration worth over $65 million with Hengrui Therapeutics to share rights to a Parkinson’s disease program.
Eli Lilly has been actively expanding its use of artificial intelligence through multiple collaborations. In October, the company partnered with Nvidia to develop what it described as one of the most powerful supercomputing platforms in the pharmaceutical industry, aimed at accelerating drug discovery and shortening development timelines.
The pharma firm has been a bit busy during the past few days. It recently indicated that it would consider restarting investment in the U.K. only if the government commits to routinely raising drug prices within the National Health Service and begins phasing out a rebate mechanism that requires drugmakers to return a significant portion of their revenues, according to a report by the Financial Times.
The U.S.-based pharma company is currently in talks with U.K. officials, pushing for changes to the existing framework that governs how medicines supplied to the NHS are priced.
The discussions involve proposals to tie reimbursement for certain therapies, such as anti-obesity drugs, to measurable patient outcomes, for example, whether a patient is able to resume work after treatment.
Insilico’s AI Partnership Gains Momentum with Lilly
Insilico’s collaboration with Eli Lilly is expanding as Insilico’s secures a deal worth up to $2.75 billion. This agreement highlights growing confidence in Insilico’s artificial intelligence platform for drug discovery. Insilico’s continues to attract major pharmaceutical partners seeking faster and more efficient ways to develop new therapies.
Deeper Look at the Collaboration Structure
The agreement reflects a multi-layered partnership designed to combine artificial intelligence capabilities with traditional pharmaceutical expertise. The financial structure typically includes upfront payments, milestone-based rewards, and potential royalties tied to successful drug development. This type of deal allows both companies to share risk while maximizing long-term value creation.
How AI Is Reshaping Early Drug Discovery
Artificial intelligence is transforming the earliest stages of drug development by rapidly analyzing massive datasets that would take humans years to process. Advanced algorithms can identify novel biological targets, predict molecular interactions, and generate optimized compounds in a fraction of the traditional timeline. This efficiency not only reduces costs but also increases the likelihood of identifying viable drug candidates.
Challenges and Limitations
Despite the promise of artificial intelligence, there are still challenges to overcome. Data quality, model transparency, and regulatory acceptance remain key concerns. Ensuring that AI-generated insights are explainable and reproducible is essential for gaining trust from regulators and the broader scientific community.
Future Outlook of AI in Drug Development
Looking ahead, AI is expected to play an even larger role across the entire drug development lifecycle, from discovery to post-market analysis. Continued investment and collaboration will likely lead to more sophisticated tools and improved outcomes. As these technologies mature, they have the potential to significantly reshape how new medicines are discovered and brought to market.
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
